Structure Therapeutics Inc. (NASDAQ:GPCR) Given Average Rating of “Buy” by Analysts

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have earned an average rating of “Buy” from the seven ratings firms that are covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $81.29.

A number of analysts have recently issued reports on GPCR shares. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reiterated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective on the stock.

Structure Therapeutics Stock Performance

NASDAQ GPCR opened at $22.82 on Friday. Structure Therapeutics has a one year low of $19.61 and a one year high of $62.74. The company’s 50 day moving average price is $26.66 and its 200 day moving average price is $33.66. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -30.84 and a beta of -2.75.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Sell-side analysts forecast that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

A number of hedge funds have recently made changes to their positions in GPCR. Deep Track Capital LP grew its position in shares of Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock worth $75,936,000 after buying an additional 1,579,492 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in Structure Therapeutics by 196.5% in the third quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock worth $54,348,000 after purchasing an additional 820,589 shares during the period. Janus Henderson Group PLC boosted its holdings in Structure Therapeutics by 18.0% in the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after purchasing an additional 602,609 shares during the period. Vestal Point Capital LP boosted its holdings in Structure Therapeutics by 105.4% in the third quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares during the period. Finally, Boxer Capital Management LLC acquired a new position in Structure Therapeutics in the fourth quarter worth $13,560,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.